Lab Surge: Laurus Leads the Pack in 52-Week High Rally

Against big market jitters, Laurus Labs has been the best-performing stock, touching the new 52-week high of ₹845.60 on July 25 and gaining nearly 25% in the past one month. The pharma and biotech firm's rally is on the heels of good Q1 performance and investor confidence in its CDMO and generic business.

Key performance highlights:

Laurus Labs posted a consolidated net income of ₹163 crore in Q1 FY26 versus ₹13 crore in the same quarter of last year

Revenue increased 31% year-on-year to ₹1,570 crore, of which CDMO contributed ₹522 crore and generics ₹1,048 crore

The company's EBITDA margin increased to 21.4%, its third consecutive one higher than 20%

Growth drivers and direction strategy:

CDMO business grew over 100%, fueled by mid-to-late stage NCE shipments and new manufacturing capacity.

Formulations business grew over 40%, led by non-ARV products and mature market portfolios.

Laurus Labs has over 110 ongoing CDMO projects in its pipeline, 90 in the human health category and 20 animal health and crop protection.

Investor sentiment and market momentum:

Laurus Labs outperformed its peer and broader indexes with a 25.12% monthly and 39.24% year-to-date return.

Strong institutional holding of 37.63% and strong ROCE of 18.5% reflect sustained investor confidence

The company's pipeline delivery and selective capex continue to drive positive sentiments

Sources: Economic Times, The Hindu, CNBC-TV18, Angel One, MarketsMojo, BusinessLine, BSE India